Aim Atezolizumab plus bevacizumab and lenvatinib have each shown efficacy as primary
systemic chemotherapies for hepatocellular carcinoma (HCC) in clinical trials. However …

Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard
of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice …

Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been
developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function …

Introduction The aim of this retrospective proof-of-concept study was to compare different
second-line treatments for patients with hepatocellular carcinoma and progressive disease …

Abstract Background & Aims In patients with unresectable hepatocellular carcinoma (HCC),
the combination of atezolizumab and bevacizumab improved progression‐free survival …

Background IMbrave150 is a phase III trial that assessed atezolizumab+ bevacizumab
(ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular …

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer
and the third leading cause of cancer mortality worldwide. The development of effective …

Simple Summary Although atezolizumab plus bevacizumab combination therapy was
approved in September 2020 as the first immune-combined therapy for hepatocellular …

Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment
of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as …

Background There is no standard of care for adjuvant therapy for patients with
hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of …